🔓
Sign in as a Member to unlock the full view of ATAI. · Full hedge fund list, every line-item carveout, cabinet conflicts, and politicians-trading detail.
Become a Member$24.50/mo already a Member? Sign in →
ATAI

Atai Beckley N.V

Sector: healthcareMedical - PharmaceuticalsNASDAQMarket Cap: $731.9M

ATAI Life Sciences is a clinical-stage biotech holding company focused on psychedelic and novel psychiatric medicines with minimal current political/regulatory footprint.

Next filing → your inbox
Govt Dependence
15/100
Regulatory Density
45/100
Lobbying Intensity
5/100
Political Signal
LOW

BusinessWhat ATAI does

ATAI Life Sciences is a Netherlands-incorporated biotech company that develops and invests in novel treatments for mental health disorders, primarily using psychedelic compounds and other experimental therapeutics. The company operates through a portfolio of subsidiary companies in preclinical and clinical development stages, with no approved products generating revenue.

Lifetime Government AwardsATAI federal contracts

ATAI doesn't hold direct federal contracts.

Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.

Smart Money · 13F HoldingsHedge funds holding ATAI

$4.9M
Total ATAI held by tracked 13F funds
2
Funds with ATAI positions
+2
Funds opened this quarter
Citadel Advisors $4M opened 2025-12-31
D.E. Shaw & Co. $1M opened 2025-12-31

Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock

No Form 4 activity recorded in the last 180 days.

Bills Affecting ATAILive legislation impacting this stock

Political ProfileWhere ATAI sits in Washington

As a pre-revenue clinical-stage biotech with no lobbying presence or politician trading activity, ATAI has minimal direct political exposure. Stock movement driven primarily by clinical trial results and FDA interactions rather than legislative/regulatory news.

Regulatory ExposureThreats & opportunities

Regulatory threats

  • FDA enforcement on psychedelic trial protocols
  • DEA scheduling decisions on psilocybin/MDMA
  • international regulatory harmonization delays

Regulatory opportunities

  • FDA Breakthrough Therapy designation expansion
  • Expanded access programs for mental health
  • Tax incentives for rare psychiatric indications
Member intelligence layer

Live signals + predictions for ATAI — for Founders

The free page above gives you the public record. Members see the real-time intelligence layer on top of it:

Become a Founder · $24.50/mo Locked rate forever · cancel anytime

Frequently AskedAbout ATAI & political exposure

Does Atai Beckley N.V (ATAI) hold federal contracts?
No direct prime contracts reported in USASpending.gov for Atai Beckley N.V. Companies in the semiconductor and AI hardware sectors often sell to the federal government via prime contractors and cloud resellers (Microsoft Azure, AWS, Lockheed Martin systems integration) rather than as direct primes.
What is ATAI political risk profile?
Government dependence: 15/100. Lobbying intensity: 5/100. Political signal: low.
How does GovGreed track ATAI political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. ATAI data is updated daily from these official federal sources.